Paclitaxel news

All news on Paclitaxel (also known as Taxol): plants, production capacities, investments and involved companies.

18 May 2026

Merck: sac‑TMT meets OS and PFS endpoints in Phase 3 TroFuse‑005 for advanced/recurrent endometrial cancer

TroFuse‑005 (776 pts) showed significant OS and PFS improvement vs chemotherapy in advanced/recurrent endometrial cancer after platinum and anti‑PD‑1/PD‑L1 therapy; ORR met; safety consistent.
30 April 2026

Merck & Co Q1 2026 Results — Sales Growth, Regulatory Approvals and Clinical Milestones

Q1 revenue $16.3B; KEYTRUDA $8.0B. GAAP loss $1.72/sh, non-GAAP loss $1.28/sh after $9.0B Cidara charge. Announced Terns acquisition; raised 2026 sales to $65.8-67.0B and non-GAAP EPS $5.04-5.16
27 February 2026

Merck's KEYTRUDA Plus Paclitaxel Boosts Survival in Platinum-Resistant Ovarian Cancer

KEYTRUDA plus paclitaxel improves overall survival in platinum-resistant ovarian cancer, regardless of PD-L1 status, as shown in the KEYNOTE-B96 trial.

Who will be producing Paclitaxel in the future?

Find out with chemXplore Alpha

Learn more